A. Adjuvant EBRT with limited fields should be considered to decrease I B locoregional recurrence B. Adjuvant brachytherapy may be considered as an alternative to decrease III B vaginal recurrence C. Adjuvant systemic therapy is under investigation II C 2: No surgical nodal staging: 100% yes (37 voters) A. Adjuvant EBRT is generally recommended for pelvic control and III B survival B. Sequential adjuvant chemotherapy may be considered to improve PFS II C and CSS C. There is more evidence to support giving chemotherapy and EBRT in II B combination rather than either treatment modality alone 9.2 In patients with high-risk, II endometrial cancer: 1: Simple hysterectomy, surgical nodal staging performed, node negative: 97.3% (36) yes, 2.7% (1) abstain (37 voters) A. Grade 1-2, LVSI negative: Recommend vaginal brachytherapy to III B improve local control B. Grade 3 or LVSI unequivocally positive:
A. Adjuvant EBRT with limited fields should be considered to decrease locoregional recurrence I B B. Adjuvant brachytherapy may be considered as an alternative to decrease vaginal recurrence III B C. Adjuvant systemic therapy is under investigation II C 2: No surgical nodal staging: 100% yes (37 voters) A. Adjuvant EBRT is generally recommended for pelvic control and survival III B B. Sequential adjuvant chemotherapy may be considered to improve PFS and CSS II C C. There is more evidence to support giving chemotherapy and EBRT in combination rather than either treatment modality alone II B 9.2 In patients with high-risk, II endometrial cancer: 1: Simple hysterectomy, surgical nodal staging performed, node negative: 97.3% (36) yes, 2.7% (1) abstain (37 voters) A. Grade 1-2, LVSI negative: Recommend vaginal brachytherapy to improve local control III B B. Grade 3 or LVSI unequivocally positive:
IGC_2015_12_02_ESMO_1_SDC1.docx